Metabolic-related diseases, including obesity and types 1 and 2 diabetes, among others, have become major health problems worldwide, with a rapid increase in recent decades. In pursuit of improved weight-loss treatments, the mechanisms of action of GLP-1 and GIP are the focus, as various treatments are being designed to mimic their effects on the regulation of glucose homeostasis, satiety, and energy balance.
The gastrointestinal peptides GLP-1 and GIP are crucial players in metabolic diseases. These hormones, released post-meal, stimulate insulin secretion, suppress glucagon release, and promote satiety. By understanding how the activity and secretion of these molecules can lead to metabolic diseases it may be possible to identify new and more efficient treatments, offering alternative paths for more effective therapies.
Important aspects to consider about GLP-1 and GIP
This white paper focuses on some of the significant analytical factors that should be considered when measuring circulating GLP-1 and GIP.
Discover Mercodia’s premium assays for gut hormones
GLP-1
The Mercodia Total GLP-1 ELISA provides a chemiluminescent method for the quantitative determination of amidated GLP-1 in human plasma and serum samples. The assay has been validated according to CLSI, FDA, and EMA guidelines.
GIP
The Mercodia Total GIP ELISA provides a method for the quantitative determination of total GIP in human samples. Total GIP ELISA has no cross-reactivity to known cross-reactants such as GLP-1, glucagon, oxyntomodulin, and glicentin.
